首页 正文

Urine PD-L1 as a non-invasive biomarker for immune checkpoint inhibitor (ICI) therapy in bladder cancer

{{output}}
Bladder cancer (BCa) is a common urological malignancy with a high recurrence rate, often within 2 years of initial diagnosis and treatment. Due to this high recurrence, near all patients require cystoscopic surveillance, which is invasive, uncomfortable, and ... ...